Language:

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response

Neurology, 2019-03, Vol.92 (10), p.e1007-e1015 [Peer Reviewed Journal]

2019 American Academy of Neurology ;Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. ;Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. 2019 American Academy of Neurology ;ISSN: 0028-3878 ;EISSN: 1526-632X ;DOI: 10.1212/WNL.0000000000007032 ;PMID: 30737333

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
Author: Kuhle, Jens ; Kropshofer, Harald ; Haering, Dieter A ; Kundu, Uma ; Meinert, Rolf ; Barro, Christian ; Dahlke, Frank ; Tomic, Davorka ; Leppert, David ; Kappos, Ludwig
Subjects: Adult ; Biomarkers - blood ; Brain - diagnostic imaging ; Disability Evaluation ; Female ; Fingolimod Hydrochloride - therapeutic use ; Humans ; Immunosuppressive Agents - therapeutic use ; Interferon beta-1a - therapeutic use ; Magnetic Resonance Imaging ; Male ; Multiple Sclerosis, Relapsing-Remitting - blood ; Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging ; Multiple Sclerosis, Relapsing-Remitting - therapy ; Neurofilament Proteins - blood ; Prognosis
Is Part Of: Neurology, 2019-03, Vol.92 (10), p.e1007-e1015
Description: OBJECTIVETo assess the value of blood neurofilament light chain (NfL) as a biomarker of recent, ongoing, and future disease activity and tissue damage and its utility to monitor treatment response in relapsing-remitting multiple sclerosis. METHODSWe measured NfL in blood samples from 589 patients with relapsing-remitting multiple sclerosis (from phase 3 studies of fingolimod vs placebo, FREEDOMS and interferon [IFN]-β-1a, TRANSFORMS) and 35 healthy controls and compared NfL levels with clinical and MRI-related outcomes. RESULTSAt baseline, NfL levels (pg/mL) were higher in patients than in healthy controls (30.5 and 27.0 vs 16.9, p = 0.0001) and correlated with T2 lesion load and number of gadolinium-enhancing T1 lesions (p < 0.0001, both). Baseline NfL levels, treatment, and number of new or enlarging T2 lesions during the studies predicted NfL levels at the end of study (all p < 0.01). High vs low baseline NfL levels were associated (estimate [95% confidence interval]) with an increased number of new or enlarging T2 lesions (ratio of mean2.64 [1.51–4.60]; p = 0.0006), relapses (rate ratio2.53 [1.67–3.83]; p < 0.0001), brain volume loss (difference in means−0.78% [−1.02 to −0.54]; p < 0.0001), and risk of confirmed disability worsening (hazard ratio1.94 [0.97–3.87]; p = 0.0605). Fingolimod significantly reduced NfL levels already at 6 months (vs placebo 0.73 [0.656–0.813] and IFN 0.789 [0.704–0.884]), which was sustained until the end of the studies (vs placebo 0.628 [0.552–0.714] and IFN 0.794 [0.705–0.894]; p < 0.001, both studies at all assessments). CONCLUSIONSBlood NfL levels are associated with clinical and MRI-related measures of disease activity and neuroaxonal damage and have prognostic value. Our results support the utility of blood NfL as an easily accessible biomarker of disease evolution and treatment response.
Publisher: United States: American Academy of Neurology
Language: English
Identifier: ISSN: 0028-3878
EISSN: 1526-632X
DOI: 10.1212/WNL.0000000000007032
PMID: 30737333
Source: MEDLINE
Alma/SFX Local Collection

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response

Searching Remote Databases, Please Wait